KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash from Operations (2019 - 2025)

Royalty Pharma's Cash from Operations history spans 7 years, with the latest figure at 827148000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 11.4% year-over-year to 827148000.0; the TTM value through Dec 2025 reached 2975902000.0, up 7.47%, while the annual FY2025 figure was 2489823000.0, 10.08% down from the prior year.
  • Cash from Operations for Q4 2025 was 827148000.0 at Royalty Pharma, up from 702615000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 1033837000.0 in Q1 2023 and bottomed at 489957000.0 in Q4 2021.
  • The 5-year median for Cash from Operations is 661423500.0 (2024), against an average of 672240428.57.
  • The largest annual shift saw Cash from Operations skyrocketed 35.57% in 2023 before it plummeted 35.71% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 489957000.0 in 2021, then grew by 16.32% to 569931000.0 in 2022, then surged by 35.57% to 772628000.0 in 2023, then fell by 3.9% to 742525000.0 in 2024, then rose by 11.4% to 827148000.0 in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Cash from Operations are 827148000.0 (Q4 2025), 702615000.0 (Q3 2025), and 742525000.0 (Q4 2024).